These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 37549912

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors.
    Hori Y, Naitoh I, Naiki-Ito A, Kawai T, Yoshida M, Kato A, Kachi K, Sahashi H, Adachi A, Toyohara T, Kito Y, Yamamoto T, Takahashi S, Kataoka H.
    Clin Transl Gastroenterol; 2024 Apr 01; 15(4):e00667. PubMed ID: 38088372
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.
    Ashkar M, Chandra S, Vege SS, Takahashi H, Takahashi N, McWilliams RR.
    Cancer Immunol Immunother; 2023 Apr 01; 72(4):895-901. PubMed ID: 36161510
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z, Zhang W, Pang L, Zeng L, Liu S, Liu J.
    Front Immunol; 2023 Apr 01; 14():1166299. PubMed ID: 37359551
    [Abstract] [Full Text] [Related]

  • 8. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May 01; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hepatobiliary and Pancreatic Adverse Events.
    Zhang HC, Wang LS, Miller E.
    Adv Exp Med Biol; 2021 May 01; 1342():339-355. PubMed ID: 34972973
    [Abstract] [Full Text] [Related]

  • 11. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
    Satish D, Lin IH, Flory J, Gerdes H, Postow MA, Faleck DM.
    Oncologist; 2023 Dec 11; 28(12):1085-1093. PubMed ID: 37285223
    [Abstract] [Full Text] [Related]

  • 12. Hepatobiliary Adverse Events.
    Abu-Sbeih H, Wang Y.
    Adv Exp Med Biol; 2020 Dec 11; 1244():271-276. PubMed ID: 32301021
    [Abstract] [Full Text] [Related]

  • 13. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
    Kramer S, van Hee K, Blokzijl H, van der Heide F, Visschedijk MC.
    J Immunother; 2023 Sep 01; 46(7):271-275. PubMed ID: 37216403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Defining the diagnostic value of hyperlipasemia for acute pancreatitis in the critically ill.
    Cohen J, MacArthur KL, Atsawarungruangkit A, Perillo MC, Martin CR, Berzin TM, Shapiro NI, Sawhney MS, Freedman SD, Sheth SG.
    Pancreatology; 2017 Sep 01; 17(2):176-181. PubMed ID: 28237616
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hyperlipasemia in critically ill dogs with and without acute pancreatitis: Prevalence, underlying diseases, predictors, and outcome.
    Prümmer JK, Howard J, Grandt LM, Obrador de Aguilar R, Meneses F, Peters LM.
    J Vet Intern Med; 2020 Nov 01; 34(6):2319-2329. PubMed ID: 32945588
    [Abstract] [Full Text] [Related]

  • 18. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y, Kim R, Yu T, Gayle JA, Wassel CL, Dreyfus J, Phatak H, George S.
    Oncologist; 2021 Nov 01; 26(11):e2002-e2012. PubMed ID: 34327774
    [Abstract] [Full Text] [Related]

  • 19. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S.
    Cancer; 2020 Dec 01; 126(23):5088-5097. PubMed ID: 32888341
    [Abstract] [Full Text] [Related]

  • 20. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.
    J Immunother Cancer; 2019 May 03; 7(1):118. PubMed ID: 31053161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.